Zoetis Inc (ZTS) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Total Revenue Chart for Zoetis Inc
Zoetis Inc (ZTS) revenue for FY2025 was USD 9.5B, a 2.3% change from FY2024. Zoetis Inc's revenue grew from USD 2.8B in 2009 to USD 9.5B in 2025 (243.0% over 16 years). Earnings per share grew from USD 0.23 in 2010 to USD 6.02 in 2025 (2537.8%). Revenue compound annual growth rate: 5-year CAGR of 7.2%, 10-year CAGR of 7.1%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $30.49B
- Implied Share Price
- $73.79
- Enterprise Value
- $38.06B
- Revenue (TTM)
- $9.53B
- EBITDA
- $4.07B
- Profit Margin
- 27.69%
- Trailing P/E
- 12.04
- Forward P/E
- 11.90
- Price/Book (MRQ)
- 9.69
- Price/Sales (TTM)
- 3.20
- EV/EBITDA
- 9.47
- EV/Revenue
- 4.00
- Dividend Yield
- 2.72%
- Book Value
- $7.84
- Free Cash Flow (FY2025)
- $2.28B
- Free Cash Flow Yield
- 7.49%
Snapshot as of 16th August 2026 — not point-in-time controlled, may lag the live market by a few days.